KR100567209B1 - 안티-이디오타입 모노클로날 항체, 악성 종양의 능동면역치료법에서의 이들의 용도 및 이들을 함유하는 조성물 - Google Patents
안티-이디오타입 모노클로날 항체, 악성 종양의 능동면역치료법에서의 이들의 용도 및 이들을 함유하는 조성물 Download PDFInfo
- Publication number
- KR100567209B1 KR100567209B1 KR1020007004270A KR20007004270A KR100567209B1 KR 100567209 B1 KR100567209 B1 KR 100567209B1 KR 1020007004270 A KR1020007004270 A KR 1020007004270A KR 20007004270 A KR20007004270 A KR 20007004270A KR 100567209 B1 KR100567209 B1 KR 100567209B1
- Authority
- KR
- South Korea
- Prior art keywords
- mab
- idiotypic
- monoclonal antibody
- monoclonal antibodies
- idiotype
- Prior art date
Links
- 230000003302 anti-idiotype Effects 0.000 title claims abstract description 17
- 201000011510 cancer Diseases 0.000 title abstract description 32
- 238000009169 immunotherapy Methods 0.000 title description 4
- 239000000203 mixture Substances 0.000 title description 2
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 241001465754 Metazoa Species 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 230000002068 genetic effect Effects 0.000 claims abstract description 7
- 230000001681 protective effect Effects 0.000 claims abstract description 5
- 210000004408 hybridoma Anatomy 0.000 claims description 14
- 241001529936 Murinae Species 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 208000005623 Carcinogenesis Diseases 0.000 claims 1
- 230000036952 cancer formation Effects 0.000 claims 1
- 231100000504 carcinogenesis Toxicity 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 150000002270 gangliosides Chemical class 0.000 abstract description 14
- 230000004044 response Effects 0.000 abstract description 5
- 239000002955 immunomodulating agent Substances 0.000 abstract description 3
- 229940121354 immunomodulator Drugs 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 210000002966 serum Anatomy 0.000 description 24
- 241000282693 Cercopithecidae Species 0.000 description 14
- 238000002965 ELISA Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 230000005875 antibody response Effects 0.000 description 10
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 7
- 230000009257 reactivity Effects 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 230000001900 immune effect Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 108010078791 Carrier Proteins Proteins 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000001189 Cyclic Peptides Human genes 0.000 description 1
- 108010069514 Cyclic Peptides Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- FDJKUWYYUZCUJX-KVNVFURPSA-N N-glycolylneuraminic acid Chemical compound OC[C@H](O)[C@H](O)[C@@H]1O[C@](O)(C(O)=O)C[C@H](O)[C@H]1NC(=O)CO FDJKUWYYUZCUJX-KVNVFURPSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000008350 antigen-specific antibody response Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000004665 defense response Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229950003063 mitumomab Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000009206 nuclear medicine Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
- C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
문헌 ["Ganglioside vaccine: anti-idiotypic monoclonal antibodies as antigen surrogates (Iglesias, E., et al. Biotechnologia Aplicada, Vol. 14, No. 1, 1997, page 50, XP-002091466)]에는, P3 MAb와는 강력하게 반응하지만 시험된 다른 안티-강글리오시드 IgM Mab와는 반응하지 않는, 7개의 IgG1 안티-이디오타입 모노클로날 항체 (MAb)가 기재되어 있다. 7개의 안티-이디오타입 MAb는 1 내지 10㎍/㎖의 농도 범위에서 NGcGM3에 대한 P3 결합을 블록킹시키는 능력을 가졌다. 이들 안티-이디오타입 중 5개는 NGcGM3에 대한 체액성 반응을 유도시킬 수 있었고, 이들은 Ab2β 및 Ab2α 안티-이디오타입 모노클로날 항체로 분류된다.
다른 한편으로는, 페레즈(Perez) 등의 문헌["What ganglioside show us about idoiotypic networks". Biotechnologia Aplicada, VOL. 14, No. 1, 1997, page 42, XP-002091467]에도 안티-강글리오시드 항체 P3가 Balb/c 마우스에서 강력한 IgG 안티-이디오타입 반응 (Ab2, 역가 1/10,000 내지 1/50,000)을 유도시킨다는 것이 기재되어 있다. 수득된 특이적 Ab2 클론의 대부분은 GM3 (NeuGc)에 대한 P3 MAb의 결합을 블록킹시킬 수 있다. 이들 항체는 상기 언급된 경우에서와 같이, 강글리고시드에 대한 천연 자기항체 반응을 유도시킬 수 있었으며, Ab2β 안티-이디오타입 항체로서 역시 분류된다.
상기 배경으로부터 명백해지는 바와 같이, 현재까지, 감마 타입 안티-이디오타입 모노클로날 항체가, 강글리오시드를 함유하는 N-글리콜릴을 인식하고, 동시에, 동물 모델에서 항종양 효과를 나타낼 수 있는 모노클로날 항체에 대해 생성되지 않았다.
Claims (8)
- 기탁 번호 ECACC 94113026 로 기탁된 하이브리도마에 의해 생성된 뮤린(murine) 안티-N-글리콜릴 강글리오시드 항체에 대해 유도시킨 감마 타입 안티-이디오타입 모노클로날 항체에 있어서,상기 안티-이디오타입 모노클로날 항체는 부다페스트 조약에 따라 ECACC에, 기탁 번호 97112901로 기탁된 하이브리도마에 의해 생성된 감마 타입 안티-이디오타입 모노클로날 항체.
- 삭제
- 제1항에 있어서, 유전적이계 동물에서 우세한 안티-이디오타입 반응을 유도시킬 수 있으며, 종양에 대한 방어 효과를 나타냄을 특징으로 하는 감마 타입 안티-이디오타입 모노클로날 항체.
- 부다페스트 조약에 따라, 1997년 11월 29일자로, 영국에 소재한 유럽 세포 배양균 콜렉션(European Collection of Cell Cultures, ECACC)에, 기탁 번호 97112901로 기탁된 제1항 또는 제3항에 따른 모노클로날 항체를 생성하는 하이브리도마 세포 라인(hybridoma cell line).
- 유효량의 제1항 또는 제3항에 따른 안티-이디오타입 모노클로날 항체를, 희석제, 보조제 또는 수송 분자와 함께 함유하는, 폐암을 포함하는 종양 치료용 약제 조성물.
- 악성 종양형성 치료를 위한, 제1항 또는 제3항에 따른 모노클로날 항체에 의해 제조되는 의약.
- 삭제
- 삭제
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU1997119A CU22702A1 (es) | 1997-10-21 | 1997-10-21 | Anticuerpos monoclonales anti - idiotipo, su uso en la inmunoterapia activa de tumores malignos, hibridoma que los produce y composiciones que los contienen |
CU119/97 | 1997-10-21 | ||
PCT/CU1998/000007 WO1999020656A1 (es) | 1997-10-21 | 1998-10-21 | Anticuerpos monoclonales anti-idiotipos, su uso en la inmunoterapia activa de tumores malignos, y composiciones que los contienen |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010031283A KR20010031283A (ko) | 2001-04-16 |
KR100567209B1 true KR100567209B1 (ko) | 2006-04-03 |
Family
ID=5459399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020007004270A KR100567209B1 (ko) | 1997-10-21 | 1998-10-21 | 안티-이디오타입 모노클로날 항체, 악성 종양의 능동면역치료법에서의 이들의 용도 및 이들을 함유하는 조성물 |
Country Status (20)
Country | Link |
---|---|
EP (1) | EP1027375B1 (ko) |
JP (1) | JP4304287B2 (ko) |
KR (1) | KR100567209B1 (ko) |
CN (1) | CN1210309C (ko) |
AR (1) | AR017369A1 (ko) |
AT (1) | ATE341564T1 (ko) |
AU (1) | AU1019999A (ko) |
BR (1) | BR9812974A (ko) |
CA (1) | CA2308142C (ko) |
CO (1) | CO5060487A1 (ko) |
CU (1) | CU22702A1 (ko) |
CY (1) | CY1105844T1 (ko) |
DE (1) | DE69836096T2 (ko) |
DK (1) | DK1027375T3 (ko) |
EA (1) | EA003366B1 (ko) |
ES (1) | ES2274584T3 (ko) |
HK (1) | HK1034264A1 (ko) |
PT (1) | PT1027375E (ko) |
SI (1) | SI1027375T1 (ko) |
WO (1) | WO1999020656A1 (ko) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
WO2011051466A1 (en) * | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0657471A1 (en) * | 1993-12-09 | 1995-06-14 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993010221A1 (en) * | 1991-11-13 | 1993-05-27 | The Regents Of The University Of California | Chimeric murine/human anti-idiotype monoclonal antibodies |
US5653977A (en) * | 1993-09-09 | 1997-08-05 | Uab Research Foundation | Anti-idiotypic antibody that mimics the GD2 antigen |
CU22420A1 (es) * | 1993-12-29 | 1996-01-31 | Centro Inmunologia Molecular | Composicion vacunal para el desarrollo de una respuesta contra gangliosidos n glicolilados y su uso para el tratamiento del cancer |
CU22585A1 (es) * | 1995-11-17 | 1999-11-03 | Centro Inmunologia Molecular | Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune. |
US5792455A (en) * | 1996-03-21 | 1998-08-11 | Sloan-Kettering Institute For Cancer Research | Anti-idiotypic antibody vaccines |
-
1997
- 1997-10-21 CU CU1997119A patent/CU22702A1/es unknown
-
1998
- 1998-10-20 CO CO98060820A patent/CO5060487A1/es unknown
- 1998-10-20 AR ARP980105212A patent/AR017369A1/es active IP Right Grant
- 1998-10-21 DK DK98952503T patent/DK1027375T3/da active
- 1998-10-21 EP EP98952503A patent/EP1027375B1/en not_active Expired - Lifetime
- 1998-10-21 ES ES98952503T patent/ES2274584T3/es not_active Expired - Lifetime
- 1998-10-21 BR BR9812974-0A patent/BR9812974A/pt not_active IP Right Cessation
- 1998-10-21 KR KR1020007004270A patent/KR100567209B1/ko not_active IP Right Cessation
- 1998-10-21 JP JP2000516993A patent/JP4304287B2/ja not_active Expired - Lifetime
- 1998-10-21 CN CNB988114887A patent/CN1210309C/zh not_active Expired - Lifetime
- 1998-10-21 DE DE69836096T patent/DE69836096T2/de not_active Expired - Lifetime
- 1998-10-21 WO PCT/CU1998/000007 patent/WO1999020656A1/es active IP Right Grant
- 1998-10-21 AT AT98952503T patent/ATE341564T1/de active
- 1998-10-21 PT PT98952503T patent/PT1027375E/pt unknown
- 1998-10-21 CA CA002308142A patent/CA2308142C/en not_active Expired - Lifetime
- 1998-10-21 EA EA200000442A patent/EA003366B1/ru not_active IP Right Cessation
- 1998-10-21 AU AU10199/99A patent/AU1019999A/en not_active Abandoned
- 1998-10-21 SI SI9830866T patent/SI1027375T1/sl unknown
-
2001
- 2001-07-10 HK HK01104753A patent/HK1034264A1/xx not_active IP Right Cessation
-
2006
- 2006-12-12 CY CY20061101788T patent/CY1105844T1/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0657471A1 (en) * | 1993-12-09 | 1995-06-14 | Centro de Inmunologia Molecular | Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours |
Also Published As
Publication number | Publication date |
---|---|
DK1027375T3 (da) | 2007-02-05 |
EA200000442A1 (ru) | 2000-10-30 |
AR017369A1 (es) | 2001-09-05 |
EP1027375A1 (en) | 2000-08-16 |
PT1027375E (pt) | 2007-01-31 |
BR9812974A (pt) | 2000-08-08 |
JP4304287B2 (ja) | 2009-07-29 |
DE69836096D1 (de) | 2006-11-16 |
CY1105844T1 (el) | 2011-02-02 |
JP2001520034A (ja) | 2001-10-30 |
AU1019999A (en) | 1999-05-10 |
HK1034264A1 (en) | 2001-10-19 |
CN1279692A (zh) | 2001-01-10 |
DE69836096T2 (de) | 2007-05-16 |
ES2274584T3 (es) | 2007-05-16 |
SI1027375T1 (sl) | 2007-02-28 |
EA003366B1 (ru) | 2003-04-24 |
CN1210309C (zh) | 2005-07-13 |
CA2308142C (en) | 2005-06-14 |
KR20010031283A (ko) | 2001-04-16 |
CA2308142A1 (en) | 1999-04-29 |
EP1027375B1 (en) | 2006-10-04 |
WO1999020656A1 (es) | 1999-04-29 |
CU22702A1 (es) | 2001-07-31 |
CO5060487A1 (es) | 2001-07-30 |
ATE341564T1 (de) | 2006-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7399849B2 (en) | Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof | |
Chatterjee et al. | Idiotypic antibody immunotherapy of cancer | |
US5270202A (en) | Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen | |
Saleh et al. | Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. | |
US6235280B1 (en) | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 | |
Bhattacharya-Chatterjee et al. | Idiotype vaccines against human T cell leukemia. II. Generation and characterization of a monoclonal idiotype cascade (Ab1, Ab2, and Ab3). | |
AU633492B2 (en) | Anti-idiotype antibodies to anti-human high molecular weight-melanoma associated antigen | |
KR100567209B1 (ko) | 안티-이디오타입 모노클로날 항체, 악성 종양의 능동면역치료법에서의 이들의 용도 및 이들을 함유하는 조성물 | |
Wikstrand et al. | Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system | |
US6063379A (en) | Anti-idiotypic monoclonal antibodies and compositions including the anti-idiotypic monoclonal antibodies | |
AU2003204088B2 (en) | Anti-idiotypic monoclonal antibodies, their use in the active immunotherapy of malignant tumors, and compositions containing them | |
MXPA00003819A (en) | Anti-idiotype monoclonal antibodies, their use in active immunotherapy of malignant tumors and compositions containing them | |
Herlyn et al. | Epitope-and antigen-specific cancer vaccines | |
US7300651B2 (en) | Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1 | |
WO1997040140A1 (en) | Gd2 anti-idiotypic antibodies and uses thereof | |
AU5398401A (en) | Anti-idiotype antibody 11D10 and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130314 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20140312 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20150310 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20160310 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20170317 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20180312 Year of fee payment: 13 |
|
EXPY | Expiration of term |